Licensing Activities and Business Development - Additional Information (Details) - USD ($) $ in Millions	1 Months Ended									3 Months Ended	9 Months Ended	12 Months Ended
	Apr. 30, 2026	Sep. 30, 2025	Jun. 30, 2025	May 31, 2025	Jan. 31, 2025	Oct. 31, 2023	May 31, 2021	Mar. 31, 2021	Sep. 30, 2019	Mar. 31, 2023	Sep. 30, 2026	Dec. 31, 2024	Dec. 29, 2022
Merger Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone recievable											$ 0.0
Contingent and sales-based milestone payments				$ 50.0
Upfront cash payment				0.0
Merger Agreement [Member] \| Development [Member] \| Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment				5.6
Merger Agreement [Member] \| Sales-based [Member] \| Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment				$ 20.0
AbbVie [Member] \| License and Stock Purchase Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Non refundable upfront fee									$ 0.6
AbbVie [Member] \| License and Stock Purchase Agreement [Member] \| Development [Member] \| Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment									18.0
AbbVie [Member] \| License and Stock Purchase Agreement [Member] \| Commercialization [Member] \| Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment									45.0
AbbVie [Member] \| License and Stock Purchase Agreement [Member] \| Sales-based [Member] \| Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment									$ 87.5
AbbVie [Member] \| License Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment											0.0
Milestone payments					$ 3.0
Roche [Member] \| License Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares issued													482,313
Future milestone payment											0.0
Non-refundable upfront payment							$ 4.0	$ 0.5
Roche [Member] \| License Agreement [Member] \| Development and Regulatory Milestone First Indication [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment							50.0
Roche [Member] \| License Agreement [Member] \| Development and Regulatory Milestone Second Indication [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment							35.0
Roche [Member] \| License Agreement [Member] \| Development and Regulatory First Indication First Milestone [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments			$ 10.0
Roche [Member] \| License Agreement [Member] \| Development and Regulatory First Indication Second Milestone [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment											15.0
Roche [Member] \| License Agreement [Member] \| Sales-based [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment							$ 120.0
Mabwell [Member] \| License Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment											0.0
Upfront payment										$ 10.0
Mabwell [Member] \| License Agreement [Member] \| Development and Regulatory First Indication First Milestone [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments						$ 5.0
Mabwell [Member] \| License Agreement [Member] \| Development and Regulatory First Indication Second Milestone [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments		$ 10.0
Mabwell [Member] \| License Agreement [Member] \| Development and Regulatory Second Indication First Milestone [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments	$ 5.0
Mabwell [Member] \| License Agreement [Member] \| Development and Regulatory [Member] \| Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment										127.5
Mabwell [Member] \| License Agreement [Member] \| Sales-based [Member] \| Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment										$ 275.0
OBB [Member] \| License Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment received												$ 0.2
Future milestone recievable											$ 0.0
OBB [Member] \| License Agreement [Member] \| Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future consideration recievable on clinical												7.0
Future consideration recievable on regulatory												35.0
Future consideration recievable on sales milestones												$ 160.0